Cannabis News Box

https://www.weednews.co/gw-pharmaceuticals-announces-acceptance-of-nda-filing-for-epidiolex/

Cannabis-based epilepsy treatment Epidiolex will cost $32,500 annually

The expensive price tag means that the parents of children with Lennox syndrome and Dravet syndrome may search for cheaper CBD-based treatments elsewhere
Bethan Rose Jenkins, Cannabis News Writer/Editorial August 29, 2018

Epilepsy sufferers may never have to worry about enduring bouts of life-threatening seizures ever again, thanks to the Food and Drug Administration (FDA) approving the world’s first ever cannabis-derived...

https://globenewswire.com/news-release/2018/06/25/1529165/0/en/GW-Pharmaceuticals-plc-and-its-U-S-Subsidiary-Greenwich-Biosciences-Announce-FDA-Approval-of-EPIDIOLEX-cannabidiol-oral-solution-the-First-Plant-derived-Cannabinoid-Prescription-Me.html

CEO of GW Pharma talks about Epidiolex getting FDA approval

The DEA must accurately categorize CBD within 90 days of the approval
Bethan Rose Jenkins, Cannabis News Writer/Editorial July 2, 2018

On Monday, Justin Gover hit a milestone in his career. He is the CEO of GW Pharmaceuticals – a company that created a cannabis-based medicine called Epidiolex. Not only is Epidiolex being used to treat...

https://www.bing.com/images/search?view=detailV2&ccid=l%2bAy8NMQ&id=F373403C60E81382E1F386AF8BA2DA97E0D3C834&thid=OIP.l-Ay8NMQhiu6s_P1Jhsy3wHaFj&mediaurl=https%3a%2f%2fstatic.independent.co.uk%2fs3fs-public%2fthumbnails%2fimage%2f2016%2f11%2f24%2f10%2fcannabis-1.jpg&exph=1536&expw=2048&q=cannabis&simid=608004940109843981&selectedIndex=32&ajaxhist=0

Rescheduling cannabis in the States: Could the decision backfire?

Rescheduling the plant means that, although it would still be a regulated drug, cannabis would become legal for medicinal use
Bethan Rose Jenkins, Cannabis News Writer/Editorial June 17, 2018

Cannabis is listed as a Schedule I narcotic, but things could be about to change. If the plant is moved to Schedule II, medical patients everywhere will rejoice. But what if the decision to reschedule...

https://www.weednews.co/gw-pharmaceuticals-announces-acceptance-of-nda-filing-for-epidiolex/

Will Epidiolex be the first cannabis-based drug to be approved as an epilepsy treatment?

Bethan Rose Jenkins, Cannabis News Writer/Editorial May 3, 2018

A cannabis-based medication for epilepsy could be the first to gain approval by the Food and Drug Administration (FDA). Created by British company GW Pharmaceuticals, cannabis-based epilepsy treatment...

https://www.medicaljane.com/2014/07/02/preliminary-study-cannabis-based-drug-may-help-battle-treatment-resistant-epilepsy/

FDA gives positive review for GW Pharmaceuticals’ cannabis-based medicine Epidiolex

Bethan Rose Jenkins, Cannabis News Writer/Editorial April 19, 2018

Epidiolex, a cannabis-based treatment for epilepsy from GW Pharmaceuticals, received a positive review from staff at the Federal Drug Administration (FDA) on Tuesday. GW Pharmaceuticals provided “substantial...

WHO declares CBD as safe for human consumption

WHO declares CBD as safe for human consumption

February 22, 2018

The World Health Organization (WHO) released a report stating CBD oil is a safe and effective medicine. The report affirms the medicine's effectiveness while adding there are no known side effects or potential...

U.S. Surgeon General supports studying medical cannabis, but opposes social use

U.S. Surgeon General supports studying medical cannabis, but opposes social use

Sara Tiradossi December 6, 2017

U.S. Surgeon General Jerome Adams said he supports medical cannabis research, but still opposes social use legalization. According to Adams, who spoke at the National Black Caucus of State Legislators’...

New study: nearly 70 percent of CBD extracts labeled incorrectly

New study: nearly 70 percent of CBD extracts labeled incorrectly

Sara Tiradossi November 10, 2017

Medical cannabis is legal in more than half of U.S. states, but it still remains illegal under federal law. The Food and Drug Administration does not in fact regulate derivatives of the plant, such as...

Pictured: Scott Gottlieb, the commissioner of the U.S. Food and Drug Administration

FDA commissioner threatens legal action against medical cannabis companies’ medical claims

Logan Lowrey-Rasmussen October 4, 2017

On Tuesday, Food and Drug Administration (FDA) Commissioner Scott Gottlieb said the agency could begin prosecuting cannabis companies who claim unproven health benefits in their products.  The FDA...

A new bill could completely change cannabis research

A new bill could completely change cannabis research

September 20, 2017

Thor Benson / Cannabis News Box Contributor If anyone knows how hard it is to study the medicinal benefits of cannabis, it’s Dr. Sue Sisley. Sisley is a physician who has worked with veterans for...

Sessions further impedes cannabis research

Sessions further impedes cannabis research

Logan Lowrey-Rasmussen August 21, 2017

An anonymous senior Drug Enforcement Agency (DEA) official claimed Attorney General Jeff Sessions had effectively blocked an Obama Administration initiative to expand the number of cannabis suppliers for...

FDA acknowledges CBDs positive health effects, calls for feedback

FDA acknowledges CBD’s positive health effects, calls for feedback

Logan Lowrey-Rasmussen August 15, 2017

FDA officials put out a call for comments in Monday’s Federal Register, seeking information about cannabidiol (CBD) and how the United Nation’s World Health Organization should designate it as a substance....

Load More Stories

Comments (0)

All Cannabis News Box Picks Reader Picks Sort: Newest
Activate Search
FDA